{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002741","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.579923+00:00","generated_at":"2026-05-22T21:42:48.253569+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptose TUSCANY trial: TUS+VEN+AZA triplet shows CRs, MRD negativity in high-risk AML","bullets":["Four patients at 40 mg TUS+VEN+AZA: three achieved CR/CRi and MRD-negative, including a TP53-mutated/CK AML patient.","Three patients at 80 mg TUS+VEN+AZA: all had blast reductions meeting CR/CRi criteria in Cycle 1; no DLTs reported.","No dose-limiting toxicities across both cohorts; safety profile favorable for the triplet combination.","Enrollment target of 18–24 patients by mid-late 2025; additional data releases expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002741","json":"https://secwatch.observer/filing/0001171843-25-002741.json","markdown":"https://secwatch.observer/filing/0001171843-25-002741.md","text":"https://secwatch.observer/filing/0001171843-25-002741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325002741/0001171843-25-002741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325002741/f8k_050225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:42:48.253569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}